NASDAQ:COGT Cogent Biosciences (COGT) Stock Forecast, Price & News $11.23 +0.03 (+0.27%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$10.90▼$11.3250-Day Range$9.85▼$12.1352-Week Range$4.13▼$18.07Volume397,584 shsAverage Volume735,627 shsMarket Capitalization$796.77 millionP/E RatioN/ADividend YieldN/APrice Target$21.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cogent Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.3% Upside$21.60 Price TargetShort InterestHealthy6.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.22) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector579th out of 1,012 stocksPharmaceutical Preparations Industry282nd out of 495 stocks 3.5 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.60, Cogent Biosciences has a forecasted upside of 92.3% from its current price of $11.23.Amount of Analyst CoverageCogent Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.36% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Cogent Biosciences has recently decreased by 15.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COGT. Previous Next 3.2 News and Social Media Coverage News SentimentCogent Biosciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for COGT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Cogent Biosciences is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.22) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cogent Biosciences (NASDAQ:COGT) StockCogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.Read More Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Stock News HeadlinesMay 28, 2023 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Stock Price Passes Below 50-Day Moving Average of $10.94May 27, 2023 | seekingalpha.comCogent Biosciences: APEX Part 2 Launched, ErbB2 And FGFR2 On TrackMay 28, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 24, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Cogent Biosciences (COGT)May 23, 2023 | markets.businessinsider.comLifeSci Capital Sticks to Their Buy Rating for Cogent Biosciences (COGT)May 23, 2023 | finance.yahoo.comCogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)May 17, 2023 | americanbankingnews.comShort Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Drops By 5.9%May 14, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Cogent Biosciences, Inc. Issued By SVB Leerink (NASDAQ:COGT)May 28, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...May 14, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Cogent Biosciences, Inc. (NASDAQ:COGT) Lifted by AnalystMay 13, 2023 | americanbankingnews.comBrokers Set Expectations for Cogent Biosciences, Inc.'s Q2 2023 Earnings (NASDAQ:COGT)May 11, 2023 | msn.comNeedham Reiterates Cogent Biosciences (COGT) Buy RecommendationMay 9, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Cogent Biosciences (COGT)May 9, 2023 | finanznachrichten.deCogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial ResultsMay 9, 2023 | msn.comRecap: Cogent Biosciences Q1 EarningsMay 3, 2023 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Shares Up 4.4%April 30, 2023 | americanbankingnews.comRobert W. Baird Begins Coverage on Cogent Biosciences (NASDAQ:COGT)April 22, 2023 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Cogent Biosciences (NASDAQ:COGT)April 20, 2023 | markets.businessinsider.comCogent Biosciences (COGT) Gets a Buy from SVB SecuritiesApril 19, 2023 | markets.businessinsider.comNeedham Sticks to Their Buy Rating for Cogent Biosciences (COGT)April 17, 2023 | finance.yahoo.comCogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic MastocytosisMarch 29, 2023 | americanbankingnews.comCogent Biosciences, Inc. Expected to Post FY2023 Earnings of ($2.77) Per Share (NASDAQ:COGT)March 28, 2023 | americanbankingnews.comCogent Biosciences' (COGT) Buy Rating Reiterated at HC WainwrightMarch 27, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Cogent BiosciencesMarch 14, 2023 | finance.yahoo.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial ResultsJanuary 26, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Cogent Biosciences (COGT)January 9, 2023 | finance.yahoo.comCogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer TherapeuticsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Company Calendar Last Earnings3/14/2023Today5/28/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees77Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.60 High Stock Price Forecast$26.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+92.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-140,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.00% Return on Assets-46.99% Debt Debt-to-Equity RatioN/A Current Ratio10.71 Quick Ratio10.71 Sales & Book Value Annual Sales$7.87 million Price / Sales101.24 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book4.95Miscellaneous Outstanding Shares70,950,000Free Float68,109,000Market Cap$796.77 million OptionableNot Optionable Beta1.71 Key ExecutivesAndrew R. RobbinsPresident, Chief Executive Officer & DirectorJohn L. GreenChief Financial & Accounting OfficerJessica SachsChief Medical OfficerJohn Edward RobinsonChief Scientific OfficerRachael EastonVice President & Head-Clinical DevelopmentKey CompetitorsAvidity BiosciencesNASDAQ:RNAPharming GroupNASDAQ:PHARANI PharmaceuticalsNASDAQ:ANIPCymaBay TherapeuticsNASDAQ:CBAYCollegium PharmaceuticalNASDAQ:COLLView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,639 shares on 5/26/2023Ownership: 0.017%Putnam Investments LLCBought 32,371 shares on 5/22/2023Ownership: 0.046%JPMorgan Chase & Co.Bought 28,073 shares on 5/18/2023Ownership: 0.380%New York State Common Retirement FundSold 14,426 shares on 5/18/2023Ownership: 0.045%AQR Capital Management LLCSold 7,228 shares on 5/16/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions COGT Stock - Frequently Asked Questions Should I buy or sell Cogent Biosciences stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" COGT shares. View COGT analyst ratings or view top-rated stocks. What is Cogent Biosciences' stock price forecast for 2023? 5 brokers have issued twelve-month price targets for Cogent Biosciences' shares. Their COGT share price forecasts range from $19.00 to $26.00. On average, they predict the company's share price to reach $21.60 in the next year. This suggests a possible upside of 92.3% from the stock's current price. View analysts price targets for COGT or view top-rated stocks among Wall Street analysts. How have COGT shares performed in 2023? Cogent Biosciences' stock was trading at $11.56 on January 1st, 2023. Since then, COGT shares have decreased by 2.9% and is now trading at $11.23. View the best growth stocks for 2023 here. Are investors shorting Cogent Biosciences? Cogent Biosciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,510,000 shares, a drop of 15.1% from the April 30th total of 5,310,000 shares. Based on an average daily trading volume, of 643,200 shares, the days-to-cover ratio is currently 7.0 days. View Cogent Biosciences' Short Interest. When is Cogent Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our COGT earnings forecast. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Tuesday, March, 14th. The technology company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.06. What ETFs hold Cogent Biosciences' stock? ETFs with the largest weight of Cogent Biosciences (NASDAQ:COGT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Vanguard U.S. Momentum Factor ETF (VFMO) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM). What is Cogent Biosciences' stock symbol? Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT." Who are Cogent Biosciences' major shareholders? Cogent Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.11%), Commodore Capital LP (6.73%), State Street Corp (4.83%), Perceptive Advisors LLC (3.22%), Suvretta Capital Management LLC (2.56%) and Geode Capital Management LLC (1.86%). Insiders that own company stock include Fairmount Funds Management Llc and John L Green. View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cogent Biosciences' stock price today? One share of COGT stock can currently be purchased for approximately $11.23. How much money does Cogent Biosciences make? Cogent Biosciences (NASDAQ:COGT) has a market capitalization of $796.77 million and generates $7.87 million in revenue each year. The technology company earns $-140,240,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. How can I contact Cogent Biosciences? Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The official website for the company is www.cogint.com. The technology company can be reached via phone at (617) 945-5576 or via email at jkopin@cogint.com. This page (NASDAQ:COGT) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.